Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ellen M. Basu

Phase I Trial of Anti-Gd2 Monoclonal Antibody Hu3F8 Plus GM-CSF: Impact of Body Weight, Immunogenicity and Anti-Gd2 Response on Pharmacokinetics and Survival

OncoImmunology

English

A Phase I/Ib Trial Targeting the Pi3k/Akt Pathway Using Perifosine: Long-Term Progression-Free Survival of Patients With Resistant Neuroblastoma

International Journal of Cancer

Cancer Research

Oncology

2016

English

Related publications

Complement-Mediated Mechanisms in Anti-Gd2 Monoclonal Antibody Therapy of Murine Metastatic Cancer

Cancer Research

Oncology

2005

English

Ocular Abnormalities in Patients Treated With a Novel Anti-Gd2 Monoclonal Antibody, Hu14.18K322A

English

A Monoclonal Antibody to O-Acetyl-Gd2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity Without Peripheral Nervous System Cross-Reactivity

PLoS ONE

Multidisciplinary

2011

English

Reducing Epitope Spread During Affinity Maturation of an Anti-Ganglioside GD2 Antibody

Journal of Immunology

Allergy

Immunology

2009

English

Anti-Cd105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-Gd2 Antibody Immunotherapy of Neuroblastoma With Activated Natural Killer Cells

Clinical Cancer Research

Cancer Research

Oncology

2019

English

Long-Term Continuous Infusion of Anti-Gd2 Antibody CH14.18/CHO in Relapsed/Refractory Neuroblastoma Patients

Journal for ImmunoTherapy of Cancer

English

Anti‐GM‐CSF Therapy in Psoriasis

British Journal of Dermatology

Dermatology

Medicine

2019

English

Humanizing Murine IgG3 Anti-Gd2 Antibody M3F8 Substantially Improves Antibody-Dependent Cell-Mediated Cytotoxicity While Retaining Targeting in Vivo

English

Comparison of Pain Outcomes Between Two Anti-Gd2 Antibodies in Patients With Neuroblastoma

Pediatric Blood and Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ellen M. Basu

Phase I Trial of Anti-Gd2 Monoclonal Antibody Hu3F8 Plus GM-CSF: Impact of Body Weight, Immunogenicity and Anti-Gd2 Response on Pharmacokinetics and Survival

A Phase I/Ib Trial Targeting the Pi3k/Akt Pathway Using Perifosine: Long-Term Progression-Free Survival of Patients With Resistant Neuroblastoma

Related publications

Complement-Mediated Mechanisms in Anti-Gd2 Monoclonal Antibody Therapy of Murine Metastatic Cancer

Ocular Abnormalities in Patients Treated With a Novel Anti-Gd2 Monoclonal Antibody, Hu14.18K322A

A Monoclonal Antibody to O-Acetyl-Gd2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity Without Peripheral Nervous System Cross-Reactivity

Reducing Epitope Spread During Affinity Maturation of an Anti-Ganglioside GD2 Antibody

Anti-Cd105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-Gd2 Antibody Immunotherapy of Neuroblastoma With Activated Natural Killer Cells

Long-Term Continuous Infusion of Anti-Gd2 Antibody CH14.18/CHO in Relapsed/Refractory Neuroblastoma Patients

Anti‐GM‐CSF Therapy in Psoriasis

Humanizing Murine IgG3 Anti-Gd2 Antibody M3F8 Substantially Improves Antibody-Dependent Cell-Mediated Cytotoxicity While Retaining Targeting in Vivo

Comparison of Pain Outcomes Between Two Anti-Gd2 Antibodies in Patients With Neuroblastoma